Leerink Partners Reiterates Outperform Rating on Fulcrum Therapeutics (FULC)

Leerink Partners analyst Joseph P. Schwartz reiterated an Outperform rating and $24.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).

The analyst comments "Data for pociredir in sickle cell disease (SCD) continue to evolve favorably with the release of the full data set from the Ph 1b PIONEER study this morning providing further confidence in the profile for this drug in SCD. We continue to hold a positive view of the potential for pociredir via its HbF inducer MOA to provide a potentially game-changing option for patients with SCD. While we understand that some investors may have liked to see a more drastic improvement vs. the previous update, and this is likely driving the stock weakness today, we note that the last update was already very strong and relatively mature so it is important to recognize that the totality of PIONEER data represent a real opportunity for pociredir in SCD where there is very high unmet need. We also note that HbF inducing MOAs such as pociredir are highly promising in this disease and FULC estimates they have an approximately 2 year head start on the next HbF competitor. Along with today's update FULC provided 4Q25 earnings. We updated our model for the print but maintain our $24PT and 75% POS estimate for pociredir in SCD. Reiterate Outperform."

For an analyst ratings summary and ratings history on Fulcrum Therapeutics click here. For more ratings news on Fulcrum Therapeutics click here.

Shares of Fulcrum Therapeutics closed at $10.89 yesterday.

You May Also Be Interested In

• Goldman Sachs Starts Excelerate Energy Inc (EE) at Buy
• Berenberg Downgrades Evotec AG (EVT:GR) (EVO) to Hold
• Stifel Starts Telesat Corporation (TSAT:CN) (TSAT) at Buy